Republic Power Faces NASDAQ Compliance Risk for Late 20-F Filing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2025
0mins
Source: Globenewswire
- Compliance Risk Notification: Republic Power received a delinquency letter from NASDAQ on November 21, 2025, due to its failure to timely file the 20-F annual report for the fiscal year ending June 30, 2025, which poses a risk to its compliance and listing status.
- Remediation Plan Deadline: The company has 60 days to submit a compliance plan, and if accepted by NASDAQ, it may receive an extension of up to 180 days until May 18, 2026, to regain compliance, which is crucial for maintaining its NASDAQ listing.
- Limited Immediate Impact: Although the company received the delinquency letter, it does not have an immediate impact on the listing of its ordinary shares on the NASDAQ Capital Market, indicating that the company still has time to take corrective actions to avoid more severe consequences.
- Disclosure Compliance: This announcement complies with NASDAQ Listing Rule 5810(b), which requires prompt disclosure of deficiency notifications, reflecting the company's commitment to transparency and regulatory compliance.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like RPGL with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on RPGL
About RPGL
Republic Power Group Limited is a provider of customized enterprise resource planning (ERP) software solutions, consulting and technical support services, and peripheral hardware to large and small to medium corporate clients and government agencies based in Singapore and Malaysia. The Company’s services and products include software development and customization services and product sales and consulting and technical support services. It offers project management in connection with its software products. Its project management services include consultation, design, development, and testing. It also sells equipment and related accessories to clients who acquired its customized software.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%
- Take-Private Agreement Signed: Fonar Corp announced the signing of a definitive agreement for a take-private sale, resulting in a 24.5% surge in pre-market shares to $18.25, indicating strong market confidence that could provide financial backing for future growth.
- Strong Market Reaction: The stock's robust performance in pre-market trading reflects optimistic investor sentiment regarding the privatization deal, potentially attracting more investor interest and enhancing the company's overall market capitalization.
- Significant Industry Impact: Fonar's privatization move may trigger similar actions among other medical device companies, prompting more firms in the sector to consider privatization to enhance operational efficiency and shareholder value.
- Future Strategic Direction: By going private, Fonar is expected to concentrate resources on its core business and optimize its operational model, thereby strengthening its market position and profitability in a highly competitive healthcare market.
Continue Reading
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
Continue Reading